These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 25654736)
41. Molecular signaling and the role of targeted therapies in bladder cancer. Black PC Minerva Urol Nefrol; 2012 Mar; 64(1):7-17. PubMed ID: 22402314 [TBL] [Abstract][Full Text] [Related]
47. DAB2IP regulates the chemoresistance to pirarubicin and tumor recurrence of non-muscle invasive bladder cancer through STAT3/Twist1/P-glycoprotein signaling. Wu K; Wang B; Chen Y; Zhou J; Huang J; Hui K; Zeng J; Zhu J; Zhang K; Li L; Guo P; Wang X; Hsieh JT; He D; Fan J Cell Signal; 2015 Dec; 27(12):2515-23. PubMed ID: 26410305 [TBL] [Abstract][Full Text] [Related]
48. TP53 and FGFR3 Gene Mutation Assessment in Urine: Pilot Study for Bladder Cancer Diagnosis. Noel N; Couteau J; Maillet G; Gobet F; D'Aloisio F; Minier C; Pfister C Anticancer Res; 2015 Sep; 35(9):4915-21. PubMed ID: 26254388 [TBL] [Abstract][Full Text] [Related]
49. Low level STK15 amplification in histologically benign urothelium of patients with bladder cancer adversely predicts patient outcome following cystectomy. Denzinger S; Stoehr R; Schwarz S; Eichenseher N; Brockhoff G; Obermann EC; Knuechel R; Blaszyk H; Hartmann A; Wild PJ Int J Oncol; 2007 Oct; 31(4):793-802. PubMed ID: 17786310 [TBL] [Abstract][Full Text] [Related]
50. Distinct mechanisms contribute to acquired cisplatin resistance of urothelial carcinoma cells. Höhn A; Krüger K; Skowron MA; Bormann S; Schumacher L; Schulz WA; Hoffmann MJ; Niegisch G; Fritz G Oncotarget; 2016 Jul; 7(27):41320-41335. PubMed ID: 27191498 [TBL] [Abstract][Full Text] [Related]
51. FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis. Hernández S; López-Knowles E; Lloreta J; Kogevinas M; Jaramillo R; Amorós A; Tardón A; García-Closas R; Serra C; Carrato A; Malats N; Real FX Clin Cancer Res; 2005 Aug; 11(15):5444-50. PubMed ID: 16061860 [TBL] [Abstract][Full Text] [Related]
52. Special Issue on Molecular Research Efforts in Urothelial Carcinoma: Summary of Included Topics. Hutterer GC Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31382543 [TBL] [Abstract][Full Text] [Related]
53. Dovitinib: rationale, preclinical and early clinical data in urothelial carcinoma of the bladder. Mazzola CR; Siddiqui KM; Billia M; Chin J Expert Opin Investig Drugs; 2014 Nov; 23(11):1553-62. PubMed ID: 25284004 [TBL] [Abstract][Full Text] [Related]
54. Primary Sarcomatoid Tumor of the Bladder: A Different Entity but the Same Approach? Molina-Cerrillo J; Martínez-Sáez O; Alonso-Gordoa T; Tirado-Zambrano P; Delgado-Vargas B; Earl J; Grande E Clin Genitourin Cancer; 2015 Dec; 13(6):493-8. PubMed ID: 26027772 [TBL] [Abstract][Full Text] [Related]
55. Methodological Considerations for Early-phase Development of Immune Checkpoint Inhibitors in Urothelial Bladder Cancer. Necchi A; Giardiello D; Mariani L Eur Urol; 2017 May; 71(5):840-841. PubMed ID: 27720533 [No Abstract] [Full Text] [Related]
56. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Knowles MA; Hurst CD Nat Rev Cancer; 2015 Jan; 15(1):25-41. PubMed ID: 25533674 [TBL] [Abstract][Full Text] [Related]
57. Genetic alterations in tp53 in recurrent urothelial cancer: a longitudinal study. Dalbagni G; Ren ZP; Herr H; Cordon-Cardo C; Reuter V Clin Cancer Res; 2001 Sep; 7(9):2797-801. PubMed ID: 11555595 [TBL] [Abstract][Full Text] [Related]
58. Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Platt FM; Hurst CD; Taylor CF; Gregory WM; Harnden P; Knowles MA Clin Cancer Res; 2009 Oct; 15(19):6008-17. PubMed ID: 19789314 [TBL] [Abstract][Full Text] [Related]
59. Transient receptor potential vanilloid type 2 (TRPV2) expression in normal urothelium and in urothelial carcinoma of human bladder: correlation with the pathologic stage. Caprodossi S; Lucciarini R; Amantini C; Nabissi M; Canesin G; Ballarini P; Di Spilimbergo A; Cardarelli MA; Servi L; Mammana G; Santoni G Eur Urol; 2008 Sep; 54(3):612-20. PubMed ID: 17977643 [TBL] [Abstract][Full Text] [Related]
60. Bladder cancer: current management and opportunities for a personalized approach. Galsky MD; Hall SJ Mt Sinai J Med; 2010; 77(6):587-96. PubMed ID: 21105122 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]